Author

A. D. Choudhury

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. S. Kibel· 2 shared M. L. Freedman· 2 shared S. C. Baca· 2 shared A. A. Hamid· 1 shared A. Bose· 1 shared A. J. Kreitzman· 1 shared A. Mitrofanova· 1 shared A. Simoneau· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. S. Kibel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivJun 21, 2022

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

N. De Sarkar, R. D. Patton, A.-L. Doebley…·G. Ha

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

DOI 10.1158/2159-8290.cd-22-0692

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 13, 2022

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

T. Tsujino, T. Takai, K. Hinohara…·L. Jia

This study uses CRISPR screens to identify genetic factors affecting PARP inhibitor sensitivity and resistance in prostate cancer, revealing novel targets and mechanisms.

DOI 10.1101/2022.04.13.488115

humangenetic perturbation / CRISPR

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 8, 2019

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart…·L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

DOI 10.1101/730135

humanbulk RNA-seq

𝕏 PostBluesky